A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma

Published:2016-03-24 Issue:5 Volume:173 Page:722-730
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Coiffier Bertrand¹,Thieblemont Catherine²,de Guibert Sophie³,Dupuis Jehan⁴,Ribrag Vincent⁵,Bouabdallah Réda⁶,Morschhauser Franck⁷,Navarro Robert⁸,Le Gouill Steven⁹,Haioun Corinne⁴,Houot Roch³,Casasnovas Olivier¹⁰,Holte Harald¹¹,Lamy Thierry³,Broussais Florence⁶,Payrard Sandrine¹²,Hatteville Laurence¹²,Tilly Hervé¹³

Affiliation:

1. Centre Hospitalier Lyon Sud; Pierre Bénite France

2. Department of Hemato-oncology - Paris Diderot 7 University; APHP - Hôpital Saint-Louis; Paris France

3. CHU de Rennes; Rennes France

4. Hopital Henri Mondor; Créteil France

5. Institut Gustave Roussy; Villejuif France

6. Institut Paoli Calmettes; Marseille France

7. CHRU - Hôpital Claude Huriez; Lille France

8. CHU Saint Eloi; Montpellier France

9. CHU Hôtel Dieu; Nantes France

10. CHU Le Bocage; Dijon France

11. Oslo University Hospital; Oslo Norway

12. Sanofi; Vitry-sur-Seine France

13. Centre Henri Becquerel; UMR918; Université de Rouen; Rouen France

Funder

Adelphi Communications Ltd

Sanofi

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13992/fullpdf

Reference26 articles.

1. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study;Advani;Journal of Clinical Oncology,2010

2. How I treat patients with diffuse large B-cell lymphoma;Armitage;Blood,2007

3. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma;Berinstein;Annals of Oncology,1998

4. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies;Blanc;Clinical Cancer Research,2011

5. Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma;Blasco;Fundamental & Clinical Pharmacology,2009

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody and immunotherapy in diffuse large B-cell lymphoma;Seminars in Hematology;2023-11

2. Exploration of the antibody–drug conjugate clinical landscape;mAbs;2023-08-28

3. Use of Payload Binding Selectivity Enhancers to Improve Therapeutic Index of Maytansinoid–Antibody–Drug Conjugates;Molecular Cancer Therapeutics;2023-07-25

4. Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis;Cancer Research and Treatment;2023-07-15

5. Combination of High-Resolution Structures for the B Cell Receptor and Co-Receptors Provides an Understanding of Their Interactions with Therapeutic Antibodies;Cancers;2023-05-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3